SONN Stock Analysis
SO
Uncovered
Sonnet Biotherapeutics Holdings Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. The company is headquartered in Princeton, New Jersey and currently employs 12 full-time employees. The company went IPO on 2005-07-27. The firm's technology, namely fully human albumin binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The firm designed the FHAB construct to improve drug accumulation in cancer tumors, well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese hamster ovary (CHO) cells. SON-080 is in various clinical stages for indications, such as chemotherapy-induced peripheral neuropathy (CIPN) and diabetic peripheral neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-1410.